Which KPIs matter, and what are the benchmarks?
| KPI | Why it matters | Industry benchmark |
|---|---|---|
| Activation rate | Sites that never activate waste startup work | 62% in North America (Tufts CSDD) |
| Enrollment against target, by site | Shows which locations carry the network | 37% of sites under enroll; 11% enroll zero (Tufts CSDD) |
| Screen failure rate | Unpaid work and patient quality | 36.3% average (Tufts CSDD) |
| Dropout rate | Lost revenue and data | 19.1% average (Tufts CSDD) |
| Startup cycle time | Speed to first patient | 31.4 weeks (Tufts CSDD) |
| Staff turnover | Study disruption | 35% to 61% at sites (SCRS) |
| Receivables over 90 days | Cash flow risk | 23% of sites report 31% to 40% of invoices over 90 days (SCRS via Clinical Leader) |
| Patient source mix | Dependence on one channel | Track your own baseline |
| Quality findings and deviations | Compliance risk and sale value | Unresolved findings reduce value (Objective IBV) |
Which are leading indicators?
Most of these measure what already happened. Leading indicators tell you what will happen next month: candidates identified per week, prescreens per week, and new referrals per week by location. A drop in any of them shows up in randomizations a month or two later.
How should leaders review them?
- Weekly: leading indicators and enrollment by study and location.
- Monthly: screen failure, dropout, receivables, staffing.
- Quarterly: activation, startup time, quality, source mix.
Why track patient source mix?
A network that depends on one channel, usually ads, is exposed when costs rise or a channel dries up. Referral volume per location is one of the steadiest leading indicators: once physician relationships are built, they keep producing study after study. See the enrollment statistics reference for all benchmarks.
Get your study in front of the right local physicians
TrialNotice builds a physician referral pipeline around one active study. We identify relevant local physicians within driving distance of your site, send study aligned direct mail, follow up by email and LinkedIn, track engagement with recipient level QR codes, and route warm responses into your site team's workflow.
Talk to TrialNoticeSources
- Clinical Trial Vanguard, "Tufts CSDD: New Insights on The Clinical Trial Industry" (SCOPE 2024)
- Applied Clinical Trials, "Can Recruitment and Retention Get Any Worse?" (Tufts CSDD screen failure study)
- Tufts CSDD, first comprehensive clinical site initiation benchmark (2018), via GlobeNewswire
- Tufts CSDD, patient recruitment and retention practices study (Jan 2013), via Fierce Biotech
- Society for Clinical Research Sites, Workforce Challenges at Clinical Research Sites
- Clinical Leader, "The Results Are In: Survey Reveals Barriers and Opportunities In Site Sustainability"
- Objective Investment Banking and Valuation, "Valuation of Clinical Research Sites: What Buyers Look For"